NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure
NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in Myeloma or Lymphoma
NCI - National Cancer Institute : How Monoclonal Antibodies Treat Cancer?
NYC-Miami Myeloma MRD 2020 Virtual Meeting, 8th of October 2020
EHA25 Virtual : Congress of the European Hematology Association - June 11 - 21, 2020
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
Allogenic CAR T Explained by Precision BioSciences
FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Velcade & Dexamethasone
Daratumumab / Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid)+ Dexamethasone for NDMM
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma
Myeloma UK Publication, intended for UK Audience: Infopack for newly diagnosed patients
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
The 20/2/20 risk stratification model for Smoldering Myeloma
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Lenalidomide (Revlimid) & Dex for RRMM
NCCN GUIDELINES FOR PATIENTS: Immunotherapy Side Effects: Immune Checkpoint Inhibitors
NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma - RRMM - CARAMBA-1